

**PB 61 of 2024**

National Health (Minimum Stockholding) Amendment Determination (No. 5) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 28 May 2024

Nikolai Tsyganov

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 June 2024 2

National Health (Minimum Stockholding) Determination 2023 2

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 5) 2024*.

 (2) This instrument may also be cited as PB 61 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 June 2024. | 1 June 2024 |
| 2. Schedule 1 | 1 June 2024. | 1 June 2024 |

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 June 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo Forte Viatris | after 31 August 2024—6 months stock by reference to usual demand of both Alphaclav Duo Forte Viatris and AlphaClav Duo Forte added together |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Anastrozole | Tablet 1 mg | Oral | Arimidex | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

3 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Benzathine benzylpenicillin | Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe | Injection | Bicillin L-A | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bisoprolol | Tablet containing bisoprolol fumarate 10 mg | Oral | Cipla Bisoprolol | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | Oral | Cipla Bisoprolol | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Bisoprolol | Tablet containing bisoprolol fumarate 5 mg | Oral | Cipla Bisoprolol | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Tracleer | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal‑500 | after 30 November 2023—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal‑500 | 6 months stock by reference to usual PBS demand |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Dolutegravir with abacavir and lamivudine | Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg | Oral | Triumeq | after 30 November 2023—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Dolutegravir with abacavir and lamivudine | Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg | Oral | Triumeq | 6 months stock by reference to usual PBS demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | Enalapril generichealth | between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand |

8 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Enalapril generichealth | between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand |

9 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | Genteal | 4 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | Genteal | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |

10 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | In a Wink Moisturising | 4 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | In a Wink Moisturising | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |

11 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Indapamide | Tablet containing indapamide hemihydrate 2.5 mg | Oral | Insig | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ipratropium | Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | Aeron 250 | between 1 June 2024 and 31 July 2024—0 months stock by reference to usual demand |
| Ipratropium | Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | Aeron 500 | between 1 June 2024 and 31 July 2024—0 months stock by reference to usual demand |

12 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Insect allergen extract‑honey bee venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Honey Bee Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Insect allergen extract‑honey bee venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Honey Bee Venom | 6 months stock by reference to usual PBS demand |

13 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Insect allergen extract‑paper wasp venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Paper Wasp Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Insect allergen extract‑paper wasp venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Paper Wasp Venom | 6 months stock by reference to usual PBS demand |

14 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | 6 months stock by reference to usual PBS demand |

15 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lithium | Tablet containing lithium carbonate 250 mg | Oral | Lithicarb | after 30 November 2023—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lithium | Tablet containing lithium carbonate 250 mg | Oral | Lithicarb | 6 months stock by reference to usual PBS demand |

16 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | after 30 November 2023—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | 6 months stock by reference to usual PBS demand |

17 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | Noumed Mycophenolate | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

18 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Permethrin | Cream 50 mg per g, 30 g | Application | Lyclear | after 30 November 2023—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Permethrin | Cream 50 mg per g, 30 g | Application | Lyclear | 6 months stock by reference to usual PBS demand |

19 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | NOUMED PIOGLITAZONE | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Pioglitazone Sandoz | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | NOUMED PIOGLITAZONE | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Pioglitazone Sandoz | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

20 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Probenecid | Tablet 500 mg | Oral | Pro‑Cid | after 30 November 2023—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Probenecid | Tablet 500 mg | Oral | Pro‑Cid | 6 months stock by reference to usual PBS demand |

21 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | Noumed Rosuvastatin | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 20 mg (as calcium) | Oral | Noumed Rosuvastatin | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 40 mg (as calcium) | Oral | Noumed Rosuvastatin | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Noumed Rosuvastatin | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

22 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Roxithromycin | Tablet 300 mg | Oral | Roximycin | between 1 May 2024 and 30 June 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Salbutamol  | Nebuliser solution 2.5 mg (as sulfate) in 2.5 ml single dose units, 30 | Inhalation | Salbutamol Cipla | between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand.  |
| Salbutamol  | Nebuliser solution 5 mg (as sulfate) in 2.5 ml single dose units, 30 | Inhalation | Salbutamol Cipla | between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand.  |

23 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | Oral | PHOSPHATE PHEBRA | after 30 November 2023—6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | Oral | PHOSPHATE PHEBRA | 6 months stock by reference to usual PBS demand |

24 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | NOUMED VALACICLOVIR | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

25 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valganciclovir | Tablet 450 mg (as hydrochloride) | Oral | Valganciclovir Viatris | 4 months stock by reference to usual demand of both Valganciclovir Viatris and Valganciclovir Mylan added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valganciclovir | Tablet 450 mg (as hydrochloride) | Oral | VALGANCICLOVIR HETERO | between 1 June 2024 and 31 July 2024—0 months stock by reference to usual demand |